TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16453952

Group type: EXPERIMENTAL
Intervention: Sutured sites (4‐0 nylon interrupted suture for 4‐mm lesions and two for 8‐mm lesions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Secondary intention closure (gel foam applied for hemostasis)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sutured sites (for 8‐mm punches)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Secondary intention closure (for 8‐mm punches)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both closure methods (for 4‐mm punches)
Number of subjects: 82
Study: 15602019

Group type: EXPERIMENTAL
Intervention: Palifermin (60 microg/kg/day for 3 days before and after conditioning therapy)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo (intravenous for 3 days before and after conditioning therapy)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 11450818

Group type: EXPERIMENTAL
Intervention: Autism
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Autism/Information
Number of subjects: 233

Group type: COMPARATOR
Intervention: No Autism
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Behavioral intentions (self)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Behavioral intentions (others)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Information about autism
Number of subjects: 233
Study: 9610075

Group type: EXPERIMENTAL
Intervention: Magnesium gluconate (Mg-g) 648 mg elemental magnesium/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Magnesium chloride (Mg-c) 640 mg elemental magnesium/day
Number of subjects: 47
Study: 7923644

Group type: EXPERIMENTAL
Intervention: Hirudin (0.6 mg/kg bolus followed by 0.2 mg/kg/hour infusion for 96 hours)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Heparin (5000 U bolus and infusion of 1000 U/h for patients < 80 kg or 1300 U/h for patients >= 80 kg)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 757

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 757
Study: 3352193

Group type: EXPERIMENTAL
Intervention: Continuous exercise for 90 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Interrupted exercise (5 min after each 25 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intermittent physical activity
Number of subjects: 12
Study: 31279641

Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients with ≥ 1% PD-L1 staining
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: PD-L1 positive patients with ≥ 50% PD-L1 staining
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Epithelioid MPM patients with high PD-L1 staining (≥ 50%)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Patients with low PD-L1 staining (< 50% cells)
Number of subjects: 214
Study: 27045204

Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 249
Study: 26147455

Group type: EXPERIMENTAL
Intervention: Intradermal injection of autologous platelet-rich plasma (PRP) alone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Microdermabrasion alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of intradermal PRP and microdermabrasion in the same session
Number of subjects: 68
Study: 23237010

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR); 2-hour sessions once a week for 10 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 55
Study: 21721071

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT‐A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 63
Study: 19196574

Group type: EXPERIMENTAL
Intervention: Full‐RITA group (n=45)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Mid‐RITA group (n=45)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Non‐RITA group (n=45)
Number of subjects: 135
Study: 16526835

Group type: EXPERIMENTAL
Intervention: Diet intervention with low-fat diets and altered carbohydrate-to-protein ratio, specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training, specific details on type and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strength training, specific details on type and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise programmes, specific details on type and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet with high protein content, specific details on dosage and duration not available.
Number of subjects: 0
Study: 15631970

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy website (MoodGYM) - trial participants
Number of subjects: 19889

Group type: COMPARATOR
Intervention: Cognitive behavior therapy website (MoodGYM) - public registrants
Number of subjects: 19889
Study: 11208835

Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant interferon alfa‐2b (rIFNalpha2b)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 247
Study: 9667800

Group type: COMPARATOR
Intervention: Troglitazone 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Troglitazone 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Troglitazone 200-600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Troglitazone (all doses)
Number of subjects: 0
Study: 8164049

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative intraperitoneal chemotherapy with cisplatin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 67
Study: 3066812

Group type: EXPERIMENTAL
Intervention: Keragen implant
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (palliative care)
Number of subjects: 130
Study: 31886854

Group type: EXPERIMENTAL
Intervention: Preoperative screening for Staphylococcus aureus nasal carriers and selective 5-day decolonization using mupirocin ointment (experimental group).
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (placebo arm of the randomized Clinical Study).
Number of subjects: 534
Study: 29324986

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1891

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1891
Study: 27075577

Group type: EXPERIMENTAL
Intervention: C1 pedicle screw fixation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lateral mass screw fixation
Number of subjects: 140
Study: 26564331

Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) applied in indoor exposure test (N=101)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) applied in outdoor exposure test (N=140)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group in indoor exposure test (N=44)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group in outdoor exposure test (N=70)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Citronella oil (100%) in outdoor exposure test
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Smell satisfaction test (N=127)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Irritation level test (N=127)
Number of subjects: 241
Study: 24251359

Group type: EXPERIMENTAL
Intervention: High-dose edoxaban
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 21905276

Group type: EXPERIMENTAL
Intervention: FIR irradiation on each acupoint for 30 min, thrice a week, for two months
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study: 18188164

Group type: EXPERIMENTAL
Intervention: Dual blockade treatment with candesartan (16 mg o.d.) and lisinopril (20 mg o.d.)
Number of subjects: 51

Group type: COMPARATOR
Intervention: High-dose lisinopril (40 mg o.d.)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dual blockade treatment with candesartan and lisinopril
Number of subjects: 51
Study: 12059892

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg/kg bolus followed by continuous infusion)
Number of subjects: 64
Study: 9522671

Group type: EXPERIMENTAL
Intervention: Clivarin 1750 (low-molecular heparin)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Aspirin 2 x 500 mg (acetylsalicylic acid)
Number of subjects: 287
Study: 7510063

Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy (treatment 3)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy and the first 2 years of the child's life (treatment 4)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sensory and developmental screening at ages 1 and 2 years (treatment 1)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Screening plus free transportation for prenatal and well‐child care (treatment 2)
Number of subjects: 400
Study: 2518855

Group type: EXPERIMENTAL
Intervention: 800 micrograms misoprostol h.s.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 micrograms misoprostol h.s.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol h.s.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 800 micrograms after supper
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol q.d.s.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 796937

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Phenylbutazone 400 mg/day
Number of subjects: 36
Study: 28209746

Group type: EXPERIMENTAL
Intervention: Onartuzumab (10 mg/kg IV) plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Onartuzumab
Number of subjects: 194
Study: 26510086

Group type: EXPERIMENTAL
Intervention: Fluvastatin + Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of Care (SOC) therapy (PEG-IFN/Ribavirin) for 48 weeks
Number of subjects: 60
Study: 23588900

Group type: EXPERIMENTAL
Intervention: Active arm (fee displayed)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control arm (fee not displayed)
Number of subjects: 61
Study: 21606531

Group type: EXPERIMENTAL
Intervention: H5N1 A/Indonesia/05/2005 vaccine (3.75 μg hemagglutinin antigen, AS03(A) adjuvanted)
Number of subjects: 4561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4561
Study: 19539098

Group type: EXPERIMENTAL
Intervention: InsuPatch device
Number of subjects: 17
Study: 16670899

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15579521

Group type: EXPERIMENTAL
Intervention: iothalamate GFR (iGFR)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: serum creatinine
Number of subjects: 1094
Study: 11716797

Group type: EXPERIMENTAL
Intervention: Intervention Group (received instructions and examples)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Group (no instructions)
Number of subjects: 39
Study: 9395926

Group type: EXPERIMENTAL
Intervention: Young adults (mean age 29 years)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Older adults (mean age 69 years)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Self-appraisal motivation in young adulthood
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Self-appraisal motivation in later adulthood
Number of subjects: 216
Study: 8136093

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 to 90 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil SR (240 to 480 mg/day)
Number of subjects: 24
Study: 30030128

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ghrelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ghrelin receptor inverse agonist (PF‐5190457)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender (females vs. males)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV ghrelin
Number of subjects: 0
Study: 26551765

Group type: EXPERIMENTAL
Intervention: Inclusion of patient comments along with standardized performance information
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Inclusion of patient comments
Number of subjects: 848
Study: 25266222

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (weekly home visits with play demonstrations)
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (daily micronutrient sprinkles)
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Combined intervention (psychosocial stimulation and micronutrient supplementation)
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1420
Study: 21928096

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin by IV bolus injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 100
Study: 20187772

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (15% weight per volume; 3 g/kg BM) for 3 h after exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink after exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion during early recovery from exercise‐induced muscle injury
Number of subjects: 10
Study: 18028434

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G‐CSF + EPO
Number of subjects: 0
Study: 16407697

Group type: EXPERIMENTAL
Intervention: Physician referral to cardiac rehabilitation
Number of subjects: 304

Group type: COMPARATOR
Intervention: Instruction to attend cardiac rehabilitation
Number of subjects: 304

Group type: COMPARATOR
Intervention: Financial barriers to cardiac rehabilitation
Number of subjects: 304
Study: 12918185

Group type: EXPERIMENTAL
Intervention: 20 mg morphine sulfate p.o. approximately one hour before surgery
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10871971

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times daily
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 9095566

Group type: EXPERIMENTAL
Intervention: Continuing education program on pain assessment and management
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5
Study: 8211024

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3095913

Group type: EXPERIMENTAL
Intervention: FPL 52694
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31412902

Group type: EXPERIMENTAL
Intervention: Enhanced Triple P for Baby plus care as usual
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mellow Bumps plus care as usual
Number of subjects: 500

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 500
Study: 29395412

Group type: EXPERIMENTAL
Intervention: Depressomassage (additional to standard physical therapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard physical therapy (control group)
Number of subjects: 43
Study: 27825591

Group type: EXPERIMENTAL
Intervention: Optimized management of HF-REF
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 34
Study: 24812900

Group type: EXPERIMENTAL
Intervention: Lingtong Capsule (LC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 23192920

Group type: EXPERIMENTAL
Intervention: 1 × 10(5) autologous CD34+ cells/kg (low-dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 × 10(6) autologous CD34+ cells/kg (high-dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study: 20889344

Group type: EXPERIMENTAL
Intervention: Foot pronation (calcaneal eversion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Foot supination (calcaneal inversion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Internal leg rotation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: External leg rotation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Leg rotation
Number of subjects: 18
Study: 17880771

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study: 15607843

Group type: EXPERIMENTAL
Intervention: Higher dose buprenorphine (HD, 8‐8‐8‐4‐2 mg/day on days 1‐5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower dose buprenorphine (LD, 2‐4‐8‐4‐2 mg/day on days 1‐5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clonidine (C, 0.2‐0.3‐0.3‐0.2‐0.1 mg QID on days 1‐5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Higher dose buprenorphine (HD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower dose buprenorphine (LD)
Number of subjects: 30
Study: 12653068

Group type: EXPERIMENTAL
Intervention: Methylene blue 0.2%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indigo carmine 0.1%
Number of subjects: 25
Study: 10405506

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 25
Study: 7548807

Group type: EXPERIMENTAL
Intervention: Triple therapy for 1 week (Group IIa, n = 16)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Triple therapy for 2 weeks (Group IIb, n = 17)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No drugs (Group I, n = 29)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Triple therapy (2 weeks) for patients whose ulcer recurred after nizatidine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Persistence of H. pylori infection
Number of subjects: 62
Study: 2209512

Group type: EXPERIMENTAL
Intervention: Instant bean flakes (174 g/d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Potato flakes (102 g/d)
Number of subjects: 7
Study: 6993442

Group type: EXPERIMENTAL
Intervention: Split-course radiotherapy (two courses of 3000 rad in 2 weeks, separated by a 3-week rest period)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Continuous radiation therapy (30 fractions of 220 rad each, total dose of 6600 rad)
Number of subjects: 109
Study: 31194785

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eucaloric control foods (n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 28130379

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Discharge hyponatremia
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Treatment-induced hyponatremia
Number of subjects: 188
Study: 26066390

Group type: EXPERIMENTAL
Intervention: Aqueous gel
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lipid fluid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lipid vehicles
Number of subjects: 8

Group type: COMPARATOR
Intervention: All products
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle distribution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 8
Study: 22874829

Group type: EXPERIMENTAL
Intervention: Association Splitting (AS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 49
Study: 20858487

Group type: EXPERIMENTAL
Intervention: BIBW 2948 BS (EGFR kinase domain inhibitor), inhalatively administered
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20550864

Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric ropivacaine (15 mg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Isobaric bupivacaine (10 mg)
Number of subjects: 117
Study: 17885567

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) plus Routine Clinical Care (RCC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC) alone
Number of subjects: 94
Study: 14631220

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable silicone gastric banding (LASGB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 100
Study: 11435650

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion in CPB
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Isoflurane through vaporiser in gas circuit of the CPB machine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of isoflurane inhalation (0.2-0.5%) + SNP in low doses (<1mg/kg/min)
Number of subjects: 75
Study: 9322449

Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous RBC (washed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous RBC (unwashed)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Liquid-stored RBC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (washed and unwashed)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (all groups)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (unwashed)
Number of subjects: 36
Study: 8384887

Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.025 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.125 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.25 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 1 microgram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 250 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACTH1-24 (various doses)
Number of subjects: 0
Study: 3529909

Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18